Date: 2013-01-03
Type of information: Grant
Company: Amakem (Belgium)
Investors: Flemish Agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: € 1.4 million
Funding type: grant
Planned used: This grant will be used to apply Amakem\'s Localized Drug Action technology to the discovery and development of novel kinase inhibitor-based therapies for Inflammatory Bowel Diseases (ulcerative colitis, Crohn\'s disease).
Others: Amakem, a kinase platform company focusing on ophthalmology, has secured a €1.4M grant from the Flemish Agency for Innovation by Science and Technology (IWT), to apply its Localized Drug Action technology to the discovery and development of novel kinase inhibitor-based therapies for Inflammatory Bowel Diseases (IBD). The company has identified locally active lead molecules acting on a number of kinases which play a role in the pathology of IBD. The IWT grant will be directed to the further development of safe therapeutics that offer the potential to impact a range of factors of the disease including impaired barrier function, inflammation, fibrosis and angiogenesis but without causing systemic side effects. The goal is for Amakem to develop candidates with in vivo proof of concept in appropriate models of IBD as well as to obtain clear indications for the disease modifying properties of these molecules.
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Immunological diseases - Digestive diseases
